Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
Executive Summary
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.
You may also be interested in...
Stock Scan December 2017: Teva Stick, Valeant Carrot Spur Generics Revival
The end-of-year stock valuations across Big Pharma jumped nearly 3% in December led by financial reassurances at Valeant and gleeful shareholder reaction to ceremonial employee sacrifices at Teva.
Stock Scan December 2017: Teva Stick, Valeant Carrot Spur Generics Revival
The end-of-year stock valuations across Big Pharma jumped nearly 3% in December led by financial reassurances at Valeant and gleeful shareholder reaction to ceremonial employee sacrifices at Teva.
Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Troubled Teva has been preparing employees for layoffs, but the final plan will reshape the generic drug giant entirely with 14,000 jobs being cut in a scramble to stabilize the company. Every business area and geography will be affected.